Abstract

PurposeTo explore the value of machine learning model based on CE-MRI radiomic features in preoperative prediction of sentinel lymph node (SLN) metastasis of breast cancer.MethodsThe clinical, pathological and MRI data of 177 patients with pathologically confirmed breast cancer (81 with SLN positive and 96 with SLN negative) and underwent conventional DCE-MRI before surgery in the First Affiliated Hospital of Soochow University from January 2015 to May 2021 were analyzed retrospectively. The samples were randomly divided into the training set (n=123) and validation set (n= 54) according to the ratio of 7:3. The radiomic features were derived from DCE-MRI phase 2 images, and 1,316 original eigenvectors are normalized by maximum and minimum normalization. The optimal feature filter and selection operator (LASSO) algorithm were used to obtain the optimal features. Five machine learning models of Support Vector Machine, Random Forest, Logistic Regression, Gradient Boosting Decision Tree, and Decision Tree were constructed based on the selected features. Radiomics signature and independent risk factors were incorporated to build a combined model. The receiver operating characteristic curve and area under the curve were used to evaluate the performance of the above models, and the accuracy, sensitivity, and specificity were calculated.ResultsThere is no significant difference between all clinical and histopathological variables in breast cancer patients with and without SLN metastasis (P >0.05), except tumor size and BI-RADS classification (P< 0.01). Thirteen features were obtained as optimal features for machine learning model construction. In the validation set, the AUC (0.86) of SVM was the highest among the five machine learning models. Meanwhile, the combined model showed better performance in sentinel lymph node metastasis (SLNM) prediction and achieved a higher AUC (0.88) in the validation set.ConclusionsWe revealed the clinical value of machine learning models established based on CE-MRI radiomic features, providing a highly accurate, non-invasive, and convenient method for preoperative prediction of SLNM in breast cancer patients.

Highlights

  • Breast cancer, the second leading cause of cancer-related death, has become the most commonly diagnosed cancer among women worldwide [1]

  • This retrospective study was approved by the Institutional Review Board and conducted under Good Clinical Practice guidelines

  • Inclusion criteria were as follows: [1] patients with breast cancer confirmed by histopathological examination, and [2] received SLN biopsy (SLNB)/ ALN dissection (ALND); [3] patients underwent dynamic contrast-enhanced MRI examination before surgery; [4] available clinical and pathological information {such as age, tumor size, BI-RADS classification, histological type and grade of invasive carcinoma, molecular subtype [according to the status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor type 2 (HER-2), and Ki-67]}

Read more

Summary

Introduction

The second leading cause of cancer-related death, has become the most commonly diagnosed cancer among women worldwide [1]. Identifying axillary lymph node (ALN) status is essential for breast cancer patients because it has great significance for the breast cancer clinical stage, treatment plan, and prognosis of patients [2]. ALN dissection (ALND) has long been used to determine the status of ALN in patients with breast cancer. SLN biopsy (SLNB) is the recommended procedure for clinical evaluation of lymph nodes in tumor-free areas of breast cancer patients. It is still an invasive procedure with complications such as arm numbness or lymphedema in 3.5–10.9% of patients [5, 7]. A noninvasive and precise diagnostic approach with higher clinical applicability is urgently needed for preoperative evaluation of sentinel lymph node metastasis (SLNM)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call